Regulatory approvals for Diabetomics’ rapid point-of-care tests for detection of glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), and insulin autoantibodies

Diabetomics obtains CE-IVD Mark on glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2) and insulin autoantibody point-of care tests for rapid assessment of type 1 diabetes and latent autoimmune diabetes in adults (LADA).

Rapid point-of-care test for determination of C-peptide levels.

Diabetomics obtains CE-IVD Mark for rapid-point-of care (POC) test for C-peptide estimation. The availability of a rapid, simple-to-use, POC test for C-peptide will facilitate staging of presymptomatic type 1 diabetes and differential diagnosis of late-onset type 1 diabetes, LADA, and maturity-onset diabetes of the young (MODY).

Scroll to Top